Clinical Trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to assess the safety of: * single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I * repeated doses of the study drug CHF6333 in subjects with BE - Part II
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-11; most recent amendment 2026-03-04.
Trial Details
NCT Number NCT06166056
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Bronchiectasis
Enrollment 45 participants
Start Date 2023-11-29
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-05